AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03227991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning Intervention
Description: The Safety Planning Intervention is a protocol driven, brief suicide prevention strategy that is a good fit for acute care settings. It involves a clinician working collaboratively with the patient to build a personalized safety plan that is documented using a templated paper form and includes warning sign identification, means restriction and personalized strategies to deescalate a suicide crisis.
Study NCT03227991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk factors and Warning signs
Description: Printed information sheet listing suicide risk factors and crisis hotlines
Study NCT00836004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg capsule
Description: 1 x 300 mg
Study NCT00836004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cleocin HCl 300 mg capsules
Description: 1 x 300 mg
Study NCT05351957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Only dry needling of the lower limbs will performed in all patients with acupunture needling
Study NCT06321835 — intervention group
Intervention type: PROCEDURE
Intervention: Endotracheal tube cuff pressure measurement
Description: This is a prospective study conducted on 200 patients undergoing urological procedures in supine, prone, lateral flank and litotomy positions. After intubation (T0), the cuff pressure was checked with a cuff manometer and adjusted at 25 cmH2O as the baseline and continuously monitored. The cuff pressure was checked again before (T1) and after achieving the final position (T2) and then at 5 (T3), 10 (T4), 15 (T5), 30, 45, 60, 90, 120, 150, 180 minutes after the position, at the end of the procedure (T6) and before extubation (T7). At postoperative 2nd and 12th hours, the patients were interviewed for sore throat, hoarseness and cough.
Study NCT01302548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRRISEPT
Description: Device containing sterile water and chlorhexidine gluconate (CHG)
Study NCT01302548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
Study NCT00729001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPOL
Description: Two-dose intramuscular injection (US subjects only)
Study NCT00729001 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IPOL
Description: Two-dose intramuscular injection (US subjects only)
Study NCT00729001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix
Description: Three-dose intramuscular injection (US subjects only)
Study NCT02337842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.4 Challenge Pool CIN-1
Description: Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10\^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10\^2 or 5x10\^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10\^4, 10\^3, 5x10\^2 or 5x10\^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10\^4 or 5x10\^3 or 10\^3 or 10\^2 or 10\^4 or 5x10\^2 or 5x10\^1RT-PCR units.
Study NCT00729001 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Infanrix
Description: Three-dose intramuscular injection (US subjects only)
Study NCT00729001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OmniHIB
Description: Three-dose intramuscular injection (US subjects only)
Study NCT00729001 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: OmniHIB
Description: Three-dose intramuscular injection (US subjects only)
Study NCT00729001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel
Description: Three-dose intramuscular injection (Canada only)
Study NCT00729001 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pentacel
Description: Three-dose intramuscular injection (Canada only)
Study NCT03664141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil
Description: Treatment with cannabis oil
Study NCT03664141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis oil
Description: Treatment with cannabis oil
Study NCT03664141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/ Regular Oil
Description: Treatment with placebo (Regular Oil)
Study NCT03664141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/ Regular Oil
Description: Treatment with placebo (Regular Oil)
Study NCT02092428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image Quality
Description: The following procedures may be conducted as part of this study:~* Coronary MRI scan with no contrast~* Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg~* MRI scan with an oral beta blocker (metoprolol)~* Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)~Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions.
Study NCT02092428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Accuracy
Description: Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
Study NCT03404167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0914
Description: Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
Study NCT00943904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interstim implant for SNS
Description: stimulates third sacral nerve root
Study NCT02337842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 80 ml of sterile water for oral administration
Study NCT02927145 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1/ ASO1
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity.
Study NCT05229081 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: vaccine education
Description: The educational content was developed based on research and expert perspectives and included general information about immunization, pneumonia, and pneumococcal vaccines, as well as vaccine myths. This information was first conveyed to the patients verbally, and then booklets with the same material were handed to them. The Pneumococcal Conjugate Vaccine 13 (PCV13) vaccination was recommended based on Infectious Disease Society of America (IDSA), Advisory Committee on Immunization Practices (ACIP), and national adult immunization guidelines.
Study NCT02504541 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate auto-injector
Description: Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels
Study NCT00109369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information and decision support for providers and patients
Description: Laboratory-based decision support, reminders, and population report cards.
Study NCT01625767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAT experiment
Description: Smokers and nonsmokers complete AAT experiment
Study NCT00899457 — intervention group
Intervention type: GENETIC
Intervention: proteomic profiling
Description: Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
Study NCT00899457 — intervention group
Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
Study NCT00899457 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
Study NCT00899457 — intervention group
Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: Collection of breath condensate.
Study NCT02242006 — intervention group
Intervention type: OTHER
Intervention: serial serum sampling for quantification of drug concentration
Study NCT00327171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.
Study NCT00327171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.
Study NCT06161090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection
Study NCT06161090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study NCT01643187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage fortified with 21 vitamins and minerals
Description: The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
Study NCT01643187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactose-free milk
Description: Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
Study NCT01121926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone HCl
Description: Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours.
Study NCT01121926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl
Description: Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours.
Study NCT01063582 — intervention group
Intervention type: OTHER
Intervention: exposure to occupational noise
Description: We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.
Study NCT01063582 — intervention group
Intervention type: PROCEDURE
Intervention: cardiovascular valuation
Description: Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
Study NCT03453970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education Program
Description: The total duration of the program will be 12 weeks with a maximum of 6 sessions of 30 minutes each. In the first session, through the EBADE questionnaire, the needs will be identified by grouping them by the 4 constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention). The interventions and the number of sessions will be adapted depending on the areas identified with barriers. These interventions will be applied in both face-to-face and telephone modalities, using the Nursing Intervention Classification and their respective activities. The interventions will be carried out by nurses who have previously received training on the proposed program. Follow-ups will be carried out every 15 days.
Study NCT01657123 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ergometry
Description: ergometry measurements
Study NCT01657123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ergometry
Description: Ergometry measurements
Study NCT03572374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAMWork App
Description: The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance.
Study NCT03572374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information Booklet
Description: Participants in the control arm will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
Study NCT03390829 — intervention group
Intervention type: OTHER
Intervention: semi-directed interviews
Description: semi-directed interviews
Study NCT04269408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: 10 NicaPlant® implants releasing 4 mg nicardipine each.
Study NCT04269408 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Both arms receive the usual standard of care.
Study NCT04269408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Both arms receive the usual standard of care.
Study NCT00608088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A warm-line was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls.
Study NCT00608088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Nurse/Peer Councelor Team
Description: Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.~The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months.
Study NCT04062812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the same citrate dosification in both types
Description: match concentrated and dilute citrate protocol
Study NCT04062812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the same citrate dosification in both types
Description: match concentrated and dilute citrate protocol
Study NCT04492410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rapid serological test
Description: screening using a rapid serological test with a drop of blood from a finger prick
Study NCT03745781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo pills
Study NCT03128463 — intervention group
Intervention type: DRUG
Intervention: Intravitreal injection of conbercept
Description: We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
Study NCT00540215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucagonlike peptide
Description: 450 nmol native form, synthetic
Study NCT00540215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucagonlike peptide
Description: 450 nmol native form, synthetic
Study NCT03851601 — intervention group
Intervention type: OTHER
Intervention: blood samples
Description: Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
Study NCT01052064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
Study NCT01191385 — intervention group
Intervention type: DRUG
Intervention: Any treatment for unresectable HCC as chosen by the physician
Description: Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
Study NCT02827708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once daily.
Study NCT02827708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration once daily.
Study NCT03624608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuryzoN Family of Devices
Description: The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
Study NCT00659477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: once daily
Study NCT03668418 — intervention group
Intervention type: DRUG
Intervention: Fluorouracil
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study NCT03668418 — intervention group
Intervention type: DRUG
Intervention: Lederfolin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study NCT03668418 — intervention group
Intervention type: DRUG
Intervention: Oxaliplatin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study NCT03379350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clamping group
Description: Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
Study NCT01050777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal meglumine antimoniate (Glucantime)
Description: Liposomes containing meglumine antimoniate
Study NCT01050777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal meglumine antimoniate
Description: Liposomal form of meglumine antimoniate